Lung Involvement in Primary Sjögren's Syndrome—An Under-Diagnosed Entity
Interstitial lung disease (ILD) represents a frequent extra-glandular manifestation of primary Sjögren's Syndrome (pSS). Limited published data regarding phenotyping and treatment exists. Advances in managing specific ILD phenotypes have not been comprehensively explored in patients with coexisting pSS. This retrospective study aimed to phenotype lung diseases occurring in a well-described pSS-ILD cohort and describe treatment course and outcomes. Between April 2018 and February 2020, all pSS patients attending our Outpatient clinic were screened for possible lung involvement. Clinical, laboratory and high-resolution computed tomography (HRCT) findings were analyzed. Patients were classified according to HRCT findings into five groups: usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), desquamative interstitial pneumonia (DIP), combined pulmonary fibrosis and emphysema (CPFE), and non-specific-ILD. Lung involvement was confirmed in 31/268 pSS patients (13%). One-third (10/31) of pSS-ILD patients were Ro/SSA antibody negative. ILD at pSS diagnosis was present in 19/31 (61%) patients. The commonest phenotype was UIP n = 13 (43%), followed by NSIP n = 9 (29%), DIP n = 2 (6 %), CPFE n = 2 (6 %), and non-specific-ILD n = 5 (16%). Forced vital capacity (FVC) and carbon monoxide diffusion capacity (DLCO) appeared lower in UIP and DIP, without reaching a significant difference. Treatment focused universally on intensified immunosuppression, with 13/31 patients (42%) receiving cyclophosphamide. No anti-fibrotic treatments were used. Median follow-up was 38.2 [12.4–119.6] months. Lung involvement in pSS is heterogeneous. Better phenotyping and tailored treatment may improve outcomes and requires further evaluation in larger prospective studies.
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.1378/chest.130.5.1489
- https://doi.org//10.3389/fimmu.2019.01600
- https://doi.org//10.1007/s10067-018-4289-6
- https://doi.org//10.1016/j.rmed.2018.12.003
- https://doi.org//10.1093/rheumatology/kev200
- https://doi.org//10.1378/chest.122.6.2150
- https://doi.org//10.1136/bmjopen-2013-003569
- https://doi.org//10.1136/ard.58.1.61
- https://doi.org//10.1148/radiol.2462070712
- https://doi.org//10.1136/annrheumdis-2014-206008
- https://doi.org//10.1136/annrheumdis-2016-210571
- https://doi.org//10.1002/art.30381
- https://doi.org//10.1002/art.1780281008
- https://doi.org//10.1111/ipd.12206
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (11)
CATEGORIES
- Radiology and Organ Imaging
- Foetal Development and Medicine
- Obstetrics and Gynaecology
- Medical Genetics (excl. Cancer Genetics)
- Medical and Health Sciences not elsewhere classified
- Dermatology
- Emergency Medicine
- Gastroenterology and Hepatology
- Geriatrics and Gerontology
- Intensive Care
- Primary Health Care
- Nephrology and Urology
- Nuclear Medicine
- Orthopaedics
- Otorhinolaryngology
- Pathology (excl. Oral Pathology)
- Family Care